Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

Simply Wall St.10-11 07:25

Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674815517?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118","is_english":true,"pubTime":"2026-10-11 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674815517","market":"hk","top_or_hot":-1,"title":"Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-11 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","article_id":"2674815517","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674815517","pubTimestamp":1791674706,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi, backed by a US$1b upfront payment.\nAll of this is landing while Regeneron Pharmaceuticals trades at US$746.54, with the share price up over the past quarter but down over the year to date. The 1 year total shareholder return of 32.9% indicates that momentum may be building again as investors...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0882574055.USD":"富达全球健康医疗A ACC","REGN":"再生元制药公司","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IBB":"生物科技指数ETF-iShares Nasdaq","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0058720904.USD":"联博国际健康护理基金A","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","IBBQ":"Invesco Nasdaq Biotechnology ETF","SNYNF":"Sanofi","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BBH":"VanEck Biotech ETF","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC"},"translate_title":"随着审判胜利和赛诺菲交易引发价值叙事，再生元制药 (REGN) 焕然一新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5,"BBH":0.6,"SNYNF":1.5,"IBB":0.6,"IBBQ":0.6,"TBXU":0.6},"content_text":"Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi, backed by a US$1b upfront payment. All of this is landing while Regeneron Pharmaceuticals trades at US$746.54, with the share price up over the past quarter but down over the year to date. The 1 year total shareholder return of 32.9% indicates that momentum may be building again as investors reassess the pipeline and risk profile. See how Regeneron Pharmaceuticals compares with other late-stage healthcare opportunities by reviewing the hand picked 34 healthcare AI stocks that could be setting up for the next leg higher. After a sharp swing over the past year and a US$1b cash injection from Sanofi, Regeneron Pharmaceuticals now sits at a crossroads. Is most of the rerating already in the rear-view mirror, or is meaningful upside still ahead as the pipeline matures and cash flows evolve? AdvertisementMost Popular Narrative: 12% Undervalued At a last close of $746.54 versus a widely followed fair value of $850.88, the current Regeneron Pharmaceuticals price sits below what that narrative implies. This puts more weight on the drug portfolio than the recent share price suggests.  Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.  See why 86 investors see Regeneron Pharmaceuticals as 12% undervalued. Based on that framework, the narrative applies a 7.55% discount rate and assumes Regeneron Pharmaceuticals can convert a larger late stage pipeline, an expanded Sanofi alliance and potential obesity exposure into higher long term earnings power than the current share price implies. It still acknowledges risks around EYLEA competition, litigation and execution on Dupixent. The result is a fair value estimate of $850.88, which sits above both the $746.54 market level and the analysts' $850.88 consensus target that is grounded in revenue growth of 9.7% a year, a profit margin assumption of 31.9% and a future P/E of 14.9x on projected 2029 earnings of $6.5b. Result: Fair Value of $850.88 (UNDERVALUED) Still, Kodiak Sciences' Zenkuda challenge in retinal disease and ongoing Libtayo and fianlimab litigation could quickly weaken the current Regeneron Pharmaceuticals undervaluation story. Find out about the key risks to this Regeneron Pharmaceuticals narrative. Next Steps If this Regeneron Pharmaceuticals story feels optimistic to you, you are not alone, although sentiment can reverse quickly so check the underlying numbers yourself. To see what others are focusing on, review the 3 key rewards Looking for more investment ideas beyond Regeneron Pharmaceuticals? Consider exploring additional opportunities, since the broader market offers a range of different risk and reward profiles that can complement a Regeneron Pharmaceuticals position.  Target potential mispricings by scanning a curated pool of companies that look cheap on quality and value filters through the 28 high quality undervalued stocks. Strengthen your defensive side by reviewing the 31 resilient stocks with low risk scores that score well on stability and lower overall business risk. Hunt for potential future leaders early by checking the 20 high quality undiscovered gems before the wider market focuses on them.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674815517","isCrawlerRequest":true}